TG Therapeutics, Inc. (TGTX)

Market Cap	6.22B
Revenue (ttm)	329.00M
Net Income (ttm)	23.38M
Shares Out	145.23M
EPS (ttm)	0.15
PE Ratio	285.40
Forward PE	40.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,578,192
Open	42.58
Previous Close	42.61
Day's Range	41.98 - 42.83
52-Week Range	12.93 - 43.32
Beta	2.30
Analysts	Strong Buy
Price Target	40.67 (-5.0%)
Earnings Date	Mar 3, 2025

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glyco...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 14, 1995
• Employees: 338
• Stock Exchange: NASDAQ
• Ticker Symbol: TGTX
• Website: https://www.tgtherapeutics.com

Financial Performance

In 2024, TG Therapeutics's revenue was $329.00 million, an increase of 40.80% compared to the previous year's $233.66 million. Earnings were $23.38 million, an increase of 84.52%.

Analyst Forecast

According to 6 analysts, the average rating for TGTX stock is "Strong Buy." The 12-month stock price forecast is $40.67, which is a decrease of -5.00% from the latest price.

Price Target

$40.67

(-5.00% downside)

Analyst Consensus: Strong Buy